Cardiac changes after stereotactic radiotherapy for early stage NSCLC cancer or lung metastasis - HALO

Phase 3

Completed

• Conditions: cardiac toxicity; lung cancer; 10082206; 10038666

• Registration Number: NL-OMON55624
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

In order to be eligible to participate in this study, the patient must meet all
of the following criteria:
- Receive SBRT treatment for stage 1A-2B NSCLC or for a solitary lung
metastasis of a solid tumor
- Closest distance between edge of tumor and heart < 3 cm, measured on the
diagnostic CT scan using lung window setting (W*=*1600 and L*=**600)

Exclusion Criteria

- a pacemaker/implantable cardioverter-defibrillator (ICD), as these cannot be
scanned in MRI
- a renal function below GFR <60 ml/min/1.7m2, because administration of MRI
contrast will then not be desirable

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified